Nintedanib Pliva

Nintedanib, the active ingredient in Nintedanib Pliva, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis and for use in combination therapy for non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Pliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib targets fibrotic and oncologic pathways in specific respiratory and cancer conditions.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when combined with standard chemotherapy. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity in adult patients.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Vomiting - Abdominal pain - Decreased appetite - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Hepatic failure or severe liver injury - Arterial thromboembolic events (e.g., myocardial infarction, stroke) - Major bleeding episodes - Gastrointestinal perforation - Severe hypertension

Before initiating therapy, clinicians should evaluate several safety considerations.

- Liver function monitoring: assess baseline enzymes and repeat regularly. - Cardiovascular assessment: screen for history of arterial thromboembolism. - Bleeding risk: avoid in patients with active bleeding or uncontrolled anticoagulation. - Gastrointestinal health: use caution in patients with ulcer disease or recent surgery. - Severe hepatic impairment: contraindicated. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Nintedanib can interact with other medicines through metabolic pathways and additive pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine). - Anticoagulants (e.g., warfarin) that may increase bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel) that may exacerbate hemorrhage.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin). - Moderate CYP3A4 inducers (e.g., phenytoin, phenobarbital). - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that add gastrointestinal bleeding risk. - Diuretics that may affect blood pressure control.